Evommune raises $30M to fund in-licensed inflammation drug
What's the deal? Evommune (NYSE: EVMN) has agreed to sell 4,966,889 shares of common stock at $6.04 each to institutional healthcare investors, raising roughly $30 million in a private placement. The clinical-stage biotech develops therapies targeting drivers of chronic inflammatory diseases. The deal is expected to close on or about November 6, 2026.
Who's in? The financing drew new and existing investors, including Adage Capital Partners, Balyasny Asset ManagementDealroom has a profile for this one. Try Dealroom →, Defilade Capital Management, OrbiMed, and Squadron Capital ManagementDealroom has a profile for this one. Try Dealroom →. Morgan Stanley and Leerink PartnersDealroom has a profile for this one. Try Dealroom → acted as placement agents; OppenheimerDealroom has a profile for this one. Try Dealroom → advised on capital markets.
What's the endgame? Evommune plans to use net proceeds to advance its clinical programs and for general corporate purposes. The capital is earmarked in part for EVO570, a newly in-licensed oral VAV1-directed molecular glue degrader.
Why now? The raise lands the same day Evommune announced it had licensed EVO570 from Hinova Pharmaceuticals, pairing fresh capital with a new pipeline asset.
The signal: For a small clinical-stage biotech, tapping dedicated healthcare funds to bankroll a freshly acquired candidate shows investors are still willing to back early-stage inflammation programs — but only those with a clear development path.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
